Want to see HK:6699 full AI Analyst Report?
Top Page
Angelalign Technology Inc.
(6699)
Select Model
Select Model
Rating:66Neutral
Price Target:
HK$90.00
▼(-0.28% Downside)
Action:Reiterated
Date:03/31/26
The score is driven primarily by solid financial strength (low leverage) and a meaningful latest-year improvement in cash flow, which reduces downside financial risk. This is tempered by inconsistent profitability over recent years and a high P/E valuation, while technical indicators are constructive but not strongly bullish due to negative MACD.
Positive Factors
Balance sheet strength
Very low leverage and a conservative capital structure provide lasting financial flexibility. This reduces solvency risk, supports funding for product development or network expansion without heavy external financing, and strengthens the firm's ability to withstand demand cycles in orthodontics.
Negative Factors
Volatile profitability and margin compression
Meaningful and persistent margin variability weakens earnings visibility and undermines operating leverage. If margins remain pressured, the company may struggle to convert sales into sustainable profits, complicating capital allocation and long-term return profiles.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low leverage and a conservative capital structure provide lasting financial flexibility. This reduces solvency risk, supports funding for product development or network expansion without heavy external financing, and strengthens the firm's ability to withstand demand cycles in orthodontics.
Read all positive factors
Angelalign Technology Inc. (6699) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$11.33B
Dividend YieldN/A
Average Volume (3M)742.42K
Price to Earnings (P/E)69.9
Beta (1Y)0.93
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees3,576
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.01
Shares Outstanding170,896,380
10 Day Avg. Volume518,175
30 Day Avg. Volume742,423
Financial Highlights & Ratios
PEG Ratio0.37
Price to Book (P/B)2.59
Price to Sales (P/S)3.49
P/FCF Ratio17.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$99.30Price Target Upside10.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.17
Revenue Forecast (FY)HK$449.02M
Angelalign Technology Inc. Business Overview & Revenue Model
Company Description
Angelalign Technology Inc. functions as an investment holding enterprise primarily dedicated to the innovation, production, and distribution of clear aligner solutions for orthodontic treatment throughout China. Their key offerings, Angel Aligner ...
How the Company Makes Money
Angelalign primarily makes money by selling clear aligner orthodontic treatment solutions to dental clinics and orthodontists. Revenue is generated from providing sets of customized clear aligners for patients and associated orthodontic product/se...
Angelalign Technology Inc. Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
86
Very Positive
Cash Flow
71
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.23B | 2.59B | 1.96B | 1.48B | 1.27B | 1.27B |
| Gross Profit | 1.39B | 1.60B | 1.23B | 920.71M | 785.69M | 826.65M |
| EBITDA | 177.56M | 293.27M | 77.34M | 154.39M | 318.65M | 372.47M |
| Net Income | 169.84M | 199.13M | 88.42M | 53.48M | 213.78M | 285.85M |
Balance Sheet | ||||||
| Total Assets | 5.59B | 5.34B | 4.95B | 4.76B | 4.49B | 4.14B |
| Cash, Cash Equivalents and Short-Term Investments | 3.49B | 3.00B | 436.83M | 3.44B | 3.65B | 3.63B |
| Total Debt | 651.66M | 114.00M | 14.48M | 65.28M | 28.20M | 30.29M |
| Total Liabilities | 2.14B | 1.82B | 1.44B | 1.35B | 884.01M | 826.11M |
| Stockholders Equity | 3.41B | 3.49B | 3.46B | 3.34B | 3.61B | 3.32B |
Cash Flow | ||||||
| Free Cash Flow | 166.46M | 523.39M | -76.78M | 51.28M | 51.48M | 241.95M |
| Operating Cash Flow | 376.79M | 712.07M | 229.79M | 165.87M | 146.87M | 441.71M |
| Investing Cash Flow | -439.06M | -1.26B | -138.82M | -981.71M | -159.77M | -182.05M |
| Financing Cash Flow | -34.78M | -175.45M | -28.46M | -187.06M | -193.61M | 2.52B |
Angelalign Technology Inc. Technical Analysis
Negative
90.25
Price Trends
75.94
Negative
71.96
Negative
66.16
Positive
Market Momentum
-2.05
Positive
31.55
Neutral
28.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6699, the sentiment is Negative. The current price of 90.25 is above the 20-day moving average (MA) of 69.69, above the 50-day MA of 75.94, and above the 200-day MA of 66.16, indicating a neutral trend. The MACD of -2.05 indicates Positive momentum. The RSI at 31.55 is Neutral, neither overbought nor oversold. The STOCH value of 28.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6699.
Angelalign Technology Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$5.57B | 9.46 | 16.76% | 3.65% | 11.07% | 48.01% | |
69 Neutral | HK$6.46B | 21.87 | 11.30% | ― | 25.24% | 7.29% | |
67 Neutral | HK$1.57B | 14.98 | 3.68% | 7.46% | 7.11% | -34.66% | |
66 Neutral | HK$11.33B | 69.91 | 4.01% | ― | ― | ― | |
62 Neutral | HK$14.34B | 7.83 | 6.64% | 4.58% | 2.34% | -22.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | HK$225.89M | >-0.01 | -11.12% | ― | -24.95% | -0.76% |
* Healthcare Sector Average
HK:6699
Angelalign Technology Inc.
66.30
13.82
26.34%
HK:1066
Shandong Weigao Group Medical Polymer Co
3.17
-2.71
-46.05%
HK:1358
PW Medtech Group Ltd.
1.09
-0.14
-11.31%
HK:0876
Kaisa Health Group Holdings Limited
2.24
1.29
135.79%
HK:3600
Modern Dental Group Limited
5.96
1.89
46.44%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
30.60
5.85
23.62%
Angelalign Technology Inc. Corporate Events
Angelalign shifts from options to RSUs, expanding long-term incentive capacity
Jun 29, 2026
Angelalign Technology Inc. plans to terminate its post-IPO share option scheme, arguing that using restricted share units as the primary long-term incentive tool better matches its current needs while preserving all existing rights for grantees un...
Angelalign renews major connected sales and supply deals for 2027-2029
Jun 25, 2026
Angelalign Technology Inc. has renewed and extended its commercial relationship with CC Dental, a company controlled by its controlling shareholder CareCapital Group, through a new 2027-2029 Clear Aligners Purchase and Sales Framework Agreement. T...
Angelalign grants performance-linked share options to senior manager
Jun 25, 2026
Angelalign Technology has granted 55,964 share options to a senior management employee under its post-IPO share option scheme, exercisable at HK$68.12 per share over a ten-year period. The options will vest in four tranches between 2026 and 2029, ...
Angelalign Shareholders Approve All AGM Resolutions and Special Dividend
May 19, 2026
Angelalign Technology Inc. reported that all resolutions tabled at its 19 May 2026 annual general meeting were passed by shareholders, including approval of the 2025 audited financial statements and broad mandates for the board to issue and repurc...
Angelalign Technology Reshapes Governance Team With New Company Secretary
May 15, 2026
Angelalign Technology Inc., a Hong Kong-listed dental technology company specialising in clear orthodontic aligners and related services, operates in the competitive medical device and oral care market with a focus on China and regional growth. Th...
Angelalign sets 2026 AGM to approve 2025 results and share issuance mandate
Apr 23, 2026
Angelalign Technology Inc. has called its annual general meeting for 9:00 a.m. on May 19, 2026, in Shanghai, where shareholders will review the audited financial statements and directors’ and auditor’s reports for the year ended Decemb...
Angelalign Elevates Chairman Feng Dai to Executive Role as Board Reshapes for Global Push
Apr 23, 2026
Angelalign Technology has re-designated long-serving board chairman Feng Dai from non-executive to executive director, effective 23 April 2026, positioning him as executive chairman with primary responsibility for strategy, corporate governance, r...
Angelalign Sets Out Board Composition and Governance Committee Roles
Apr 23, 2026
Angelalign Technology Inc. has disclosed the current composition of its board of directors, detailing a mix of executive and independent non-executive directors and formalising their respective roles. The move clarifies the company’s governa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.